ArticleBioinformatics advances2025
A comprehensive bioinformatic evaluation of the NTRK family's potential as prognostic biomarkers in breast cancer.
Article in Bioinformatics advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: Breast cancer (BC), with its rising prevalence and mortality rate, is one of the most significant human health issues. The family of transmembrane tyrosine kinases that promote neuronal growth includes the neurotrophic tyrosine kinase receptors (NTRKs). NTRK1-3 genes encode the members of this family. Alterations of NTRK genes can induce carcinogenesis both in neurogenic and non-neurogenic cells. The prevalence of NTRK gene fusion is under 1% in solid tumours but is highly encountered in rare tumours. Since the prognostic values of NTRK families' expression in various types of cancer are becoming increasingly evident, we aimed to conduct a comprehensive bioinformatics study evaluating the prognostic significance of the NTRK family in BC. Online bioinformatic databases including TCGA, UALCAN, Kaplan-Meier plotter, bc-GenExMiner, cBioPortal, STRING, Enrichr, and TIMER were utilized for analysis. Results: High levels of NTRK2 and 3 demonstrated better associations with overall survival (OS) and recurrence-free survival (RFS) in BC patients ( Availability and implementation: All data generated or analysed during this study are included in this published article.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.